Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...

Nelson Peltz’s Trian Fund Management plans to push Solventum (SOLV) to separate more of its businesses after the company sold its filtration ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

In January, activist investor Nelson Peltz's Trian Fund Management said in a letter to Solventum shareholders that the company's spin-off from 3M had not been living up to potential. Trian ...

The most notable increase was Solventum Corp (NYSE:SOLV), with an additional 1,336,564 shares, bringing the total to 8,462,819 shares. This adjustment represents a significant 18.76% increase in share ...

Inside of 3M, Solventum averaged 3-4% organic growth ... Leveraging the 50+ years’ operating experience of our Founding Partners, Nelson Peltz and Peter May, Trian seeks to invest in high ...

Investing.com -- Activist investor Trian Fund Management is reportedly planning to urge Solventum to separate additional businesses following the company’s $4.1 billion deal to sell its filtration ...

Solventum Shares Are Up Today ... its bioproduction portfolio with expected long-term growth. Vandana Singh Nelson Peltz's Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election ...

Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare products, was spun out from 3M in April 2024.

Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current ...

Feb 26 (Reuters) - Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum (SOLV.N), opens new tab for further business separations following the company's $4.1 billion ...